Shire PLC (LON:SHP)‘s stock had its “overweight” rating reissued by equities researchers at Jefferies Group in a research note issued on Wednesday. They currently have a GBX 6,300 ($76.78) price target on the biopharmaceutical company’s stock. Jefferies Group’s target price points to a potential upside of 22.43% from the company’s previous close.

SHP has been the subject of several other research reports. JPMorgan Chase & Co. reissued an “overweight” rating and issued a GBX 6,300 ($76.78) price target on shares of Shire PLC in a research report on Tuesday, August 16th. Royal Bank Of Canada reissued an “outperform” rating on shares of Shire PLC in a research report on Friday, July 22nd. Shore Capital reissued a “buy” rating on shares of Shire PLC in a research report on Tuesday, August 30th. Deutsche Bank AG reissued a “buy” rating and issued a GBX 6,200 ($75.56) price target on shares of Shire PLC in a research report on Wednesday, October 12th. Finally, Credit Suisse Group AG raised their price objective on shares of Shire PLC from GBX 5,000 ($60.94) to GBX 5,200 ($63.38) and gave the stock an “outperform” rating in a report on Wednesday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eighteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of GBX 5,888.75 ($71.77).

Analyst Recommendations for Shire PLC (LON:SHP)

Shares of Shire PLC (LON:SHP) opened at 5159.00 on Wednesday. The firm has a 50-day moving average price of GBX 5,022.47 and a 200-day moving average price of GBX 4,625.73. The firm’s market capitalization is GBX 35.23 billion. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,377.00.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

The company also recently declared a dividend, which was paid on Friday, October 7th. Stockholders of record on Thursday, September 8th were given a dividend of GBX 3.51 ($0.04) per share. The ex-dividend date of this dividend was Thursday, September 8th. This represents a dividend yield of 0.07%.

In other news, insider Dominic Blakemore purchased 133 shares of Shire PLC stock in a transaction dated Friday, September 30th. The shares were bought at an average cost of GBX 5,010 ($61.06) per share, with a total value of £6,663.30 ($8,121.02).

Shire PLC Company Profile

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with's FREE daily email newsletter.